Skip to Main Content

Author Details

Jun Yao
The University of Texas MD Anderson Cancer Center
1997
99
49
PMIDPaper TitleJournal TitlePublished Year
36724291Tumor-associated nonmyelinating Schwann cell-expressed <i>PVT1</i> promotes pancreatic cancer kynurenine pathway and tumor immune exclusion.Sci Adv2023
36991019Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance.Nat Commun2023
37478190Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer.Sci Adv2023
34822775The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.Cancer Cell2022
35538070EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation.Nat Commun2022
35420681Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1.Cancer Discov2022
36506030The emerging role of DEAD/H-box helicases in hepatitis B virus infection.Front Cell Infect Microbiol2022
35941331miRNA-23b-5p affects the proliferation, migration and invasion of osteosarcoma by targeting TMEM127.Discov Oncol2022
36239936Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.JAMA Netw Open2022
36282572A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.J Clin Invest2022
35278434Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.J Biol Chem2022
33011748TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.Mod Pathol2021
33547304Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.Nat Commun2021
33509942Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.Cancer Res2021
33855973TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.J Clin Invest2021
34873175Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.Nat Commun2021
34588424IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming.Oncogenesis2021
34433039Evading immune surveillance via tyrosine phosphorylation of nuclear PCNA.Cell Rep2021
33986289Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation.Nat Commun2021
34117030Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition.Cancer Res2021
34140640Cell-type deconvolution analysis identifies cancer-associated myofibroblast component as a poor prognostic factor in multiple cancer types.Oncogene2021
31570790Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer.Oncogene2020
31996688Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.Nat Commun2020
33338401A Surge of DNA Damage Links Transcriptional Reprogramming and Hematopoietic Deficit in Fanconi Anemia.Mol Cell2020
32439835Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy.Cell Death Dis2020
32461334Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases.Sci Transl Med2020
32229723CIC is a critical regulator of neuronal differentiation.JCI Insight2020
32368395Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma.Am J Cancer Res2020
32156778Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.Cancer Res2020
30361685Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.Oncogene2019
31704972CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.Nat Commun2019
31557131YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.JCI Insight2019
31239273Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.Cancer Res2019
31519911Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.Nat Commun2019
30918400Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.Nature2019
31160797Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.Nat Immunol2019
30631154LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition.Cell Res2019
28925391EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.Oncogene2018
29606613Far Upstream Element-Binding Protein 1 Regulates LSD1 Alternative Splicing to Promote Terminal Differentiation of Neural Progenitors.Stem Cell Reports2018
29606349Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer.Cancer Cell2018
29438695Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.Cancer Cell2018
28877935Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.Cancer Prev Res (Phila)2017
28232723Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.Nat Commun2017
28114269A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.Nat Cell Biol2017
28218907The LINK-A lncRNA interacts with PtdIns(3,4,5)P<sub>3</sub> to hyperactivate AKT and confer resistance to AKT inhibitors.Nat Cell Biol2017
29130936JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.J Clin Invest2017
27045022Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.Cancer Immunol Res2016
27960087Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.Cancer Cell2016
27991913Linking genomic reorganization to tumor initiation via the giant cell cycle.Oncogenesis2016
27572267Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.Nat Commun2016
  • 1 - 50 of 99

Recommended Authors

Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 27
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 15
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 21
Ruby Yun-Ju Huang
National Taiwan University College of Medicine
Career Start Year 2008
Number of shared co-authors 2
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 0
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 5
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 3
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 1
Nehad M Alajez
College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation
Career Start Year 2004
Number of shared co-authors 0
Silvano Piazza
International Centre for Genetic Engineering and Biotechnology
Career Start Year 2004
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 23
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 17
Yuelin J Zhu
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 0
Limei Hu
Aier Eye Hospital of Wuhan University
Career Start Year 2001
Number of shared co-authors 7
Wei Zhang
Children's Hospital, Zhejiang University School of Medicine
Career Start Year 2001
Number of shared co-authors 2
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 1
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 2
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 14
Woong-Yang Park
Samsung Genome Institute, Samsung Medical Center
Career Start Year 1995
Number of shared co-authors 9
Phillip Buckhaults
University of South Carolina
Career Start Year 1993
Number of shared co-authors 1
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 13
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 1
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 3
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 21
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 27
Patrick Kwok-Shing Ng
The University of Texas MD Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 15
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 14

Collaborators

Mien-Chie Hung
Co-authored papers 31
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 18
Gabriel N Hortobagyi
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Wai-Kwan Alfred Yung
University of Texas M.D. Anderson Cancer Center
Co-authored papers 9
Liuqing Yang
University of Tennessee Health Science Center
Co-authored papers 8
Anil K Sood
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Yi-Hsin Elsa Hsu
Taipei Medical University
Co-authored papers 5
Qi Zhao
University of Science and Technology Liaoning
Co-authored papers 5
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Yuri Nikolsky
Co-authored papers 5
Andrea L Richardson
Co-authored papers 5
Kenneth Aldape
National Cancer Institute
Co-authored papers 4
Tatiana Nikolskaya
Co-authored papers 4
Pedram Argani
The Johns Hopkins Hospital
Co-authored papers 4
Suyun Huang
Virginia Commonwealth University
Co-authored papers 4
Frederick F Lang
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 4
Howard Colman
Huntsman Cancer Institute, University of Utah
Co-authored papers 4
Dimpy Koul
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Otavia L Caballero
Ludwig Institute for Cancer Research Ltd.
Co-authored papers 3
Youqiong Ye
Co-authored papers 3
Erik P Sulman
NYU Grossman School of Medicine
Co-authored papers 3
Anirban Maitra
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Robert L Strausberg
Ludwig Institute for Cancer Research
Co-authored papers 3
Timothy P Heffernan
Co-authored papers 3
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 3
Kay-Hooi Khoo
Co-authored papers 3
Patricia S Steeg
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 2
Sunil R Lakhani
University of Queensland
Co-authored papers 2
Wei Yang
Co-authored papers 2
Release 1.2